Bristol-Myers Squibb Co. et al v. AstraZeneca Pharmaceuticals LP et al
| Bristol-Myers Squibb Co., E. R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., Dr. Tasuku Honjo and Dana-Farber Cancer Institute, Inc. |
| AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd. |
| 1:2023cv00459 |
| April 25, 2023 |
| US District Court for the District of Delaware |
| Matthew F Kennelly |
| Patent |
| 35 U.S.C. § 271 Patent Infringement |
| Plaintiff |
Docket Report
RSS Track this Docket
This docket was last retrieved on June 8, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 19
SO ORDERED, re #16 STIPULATION TO EXTEND TIME the Deadline for AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd. to Answer, Move or Otherwise Respond to the Complaint to June 7, 2023. Ordered by Judge Matthew F Kennelly on 6/8/2023. (twk)
|
|
Filing 18
SO ORDERED, re #17 STIPULATION and Proposed Order Regarding Case Consolidation. Pursuant to Federal Rule of Civil Procedure 42(a), C.A. No. 22-cv-346-MFK and C.A. No. 23-cv-459-MFK are consolidated for all purposes up to and including trial. C.A. No. 22-cv-346-MFK shall be the lead case and all papers shall be filed in C.A. No. 22-cv-346-MFK (consolidated). Signed by Judge Matthew F Kennelly on 6/5/2023. (twk) (Main Document 18 replaced on 6/5/2023) (twk).
|
| Filing 17 STIPULATION and Proposed Order Regarding Case Consolidation by Bristol-Myers Squibb Co., E. R. Squibb & Sons, L.L.C., Dana-Farber Cancer Institute, Inc., Tasuku Honjo, Ono Pharmaceutical Co., Ltd.. (Attachments: #1 Exhibit A, #2 Exhibit B)(Farnan, Michael) |
| Filing 16 STIPULATION TO EXTEND TIME the Deadline for AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd. to Answer, Move or Otherwise Respond to the Complaint to June 7, 2023 - filed by AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd.. (Joyce, Alexandra) |
|
Filing 15
SO ORDERED, regarding D.I. #14 Stipulation filed by AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd. (Notice of Compliance deadline set for 5/31/2023.) Signed by Judge Matthew F Kennelly on 5/11/2023. (apk)
|
| Filing 14 STIPULATION and [Proposed] Order Regarding Service of Process on AstraZeneca UK Ltd. and to Extend Defendants' Response Time to Complaint by AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd.. (Joyce, Alexandra) |
| Pro Hac Vice Attorney Shauna M. Kramer for AstraZeneca Pharmaceuticals, LP and AstraZeneca UK Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:22-cv-00346-MFK, 1:23-cv-00079-MFK, 1:23-cv-00459-MFK(mpb) |
| Filing 13 MOTION for Pro Hac Vice Appearance of Attorney Shauna M. Kramer - filed by AstraZeneca Pharmaceuticals, LP, AstraZeneca UK Ltd., AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Joyce, Alexandra) |
|
SO ORDERED, regarding D.I. #13 MOTION for Pro Hac Vice Appearance of Attorney Shauna M. Kramer. Signed by Judge Matthew F Kennelly on 5/4/2023. (apk)
|
| Case Assigned to Judge Matthew F Kennelly of the United States District Court for the Northern District of Illinois (due to related cases). Please include the initials of the Judge (MFK) after the case number on all documents filed. (rjb) |
| Filing 12 Letter to The Honorable Colm F. Connolly and The Honorable Matthew F. Kennelly from Michael J. Farnan regarding Response to AstraZeneca's May 2, 2023 Letter - re (114 in 1:22-cv-00346-MFK, 89 in 1:17-cv-01028-CFC, 9 in 1:23-cv-00459-UNA) Letter. (Farnan, Michael) |
| Filing 11 NOTICE of Appearance by Daniel M. Silver on behalf of AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd. (Silver, Daniel) |
| Filing 10 NOTICE of Appearance by Alexandra M. Joyce on behalf of AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd. (Joyce, Alexandra) |
| Filing 9 Letter to The Honorable Colm F. Connolly, The Honorable Matthew F. Kennelly, and John A. Cerino, Clerk of the Court from Daniel M. Silver, Esq. regarding Consolidation. (Silver, Daniel) |
| Filing 8 SUMMONS Returned Executed by Tasuku Honjo, Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., E. R. Squibb & Sons L.L.C., Dana-Farber Cancer Institute, Inc..AstraZeneca Pharmaceuticals LP served on 4/26/2023, answer due 5/17/2023. (Farnan, Michael) |
| Filing 7 Summons Issued as to AstraZeneca Pharmaceuticals LP on 4/25/2023. (mkr) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Dana-Farber Cancer Institute (mkr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bristol-Myers Squibb Co. for E. R. Squibb & Sons L.L.C., and Bristol-Myers Squibb Co. has no parent corporation - filed by Bristol-Myers Squibb Co. and E. R. Squibb & Sons L.L.C. (mkr) |
| Filing 4 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Ono Pharmaceutical Co., Ltd. (mkr) |
| Filing 3 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,402,899 B2. (mkr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) |
| Filing 1 COMPLAINT filed with Jury Demand against AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd. (Filing fee $ 402, receipt number ADEDC-4121034) - filed by Tasuku Honjo, Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., E. R. Squibb & Sons L.L.C., and Dana-Farber Cancer Institute, Inc. (Attachments: #1 Exhibit 1, #2 Civil Cover Sheet) (mkr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
